Product Dossier
ZYTORVI
Product Dossier for ZYTORVI (toripalimab, Dr Reddys Laboratories). ARTG record, PBS listing, PBAC outcomes, AusPAR — compiled by arcimedes.
- Sponsor: Dr Reddys Laboratories
- Active ingredient: toripalimab
- Therapeutic area: Oncology
- Same area: TALZENNA
- Same area: ZARZIO
What it is
ZYTORVI is a toripalimab 240 mg/6 mL concentrated injection supplied in vials for intravenous infusion.
Approved indications
— Recurrent or metastatic nasopharyngeal carcinoma.
PBS listing
ZYTORVI 240 mg in 6 mL solution concentrate for intravenous infusion is listed on the PBS with streamlined restriction. The ex-manufacturer price is A$9457.03.
Regulatory history
ZYTORVI was first registered on the ARTG on 21 January 2025. In March 2025, the PBAC recommended its listing for recurrent or metastatic nasopharyngeal carcinoma.